S

Sangel Capital

10 employees

one of the earliest globally operating professional biomedical venture capital institutions in China

Investor insights

Sectors invested in

Health Care11
Biotechnology10
Medical5
biotechnology5
Biopharma4
Health Diagnostics3
Pharmaceutical3
cancer3
clinical trials3
biochemistry3
immuno-oncology3
r&d3
innovation3
tumour immunology3
oncology3
viruses3
immunotherapy3
drug development2
Oncology2
CNS2

Funding rounds participated in

$7.5M sweet spot round size

Most of their 23 investments are in rounds between $1.6M and $20M

Investor type

Venture Capital

Basic info

Industry

venture capital and private equity principals

Sectors

Date founded

2009

Investments made

U

Undisclosed raised $14M on March 7, 2023

Investors: 苏州凯风正德投资管理有限公司 and Sangel Capital

U

Undisclosed raised $1.6M on March 15, 2022

Investors: Sangel Capital

U

Undisclosed raised $30M on December 31, 2021

Investors: Sangel Capital

A

Aucta Pharmaceuticals raised undisclosed on March 10, 2021

Investors: 上海长江国弘投资管理有限公司, 苏州凯风正德投资管理有限公司 and Sangel Capital

D

Denovo Biopharma raised $46M on December 10, 2020

Investors: 盈科创新资产管理有限公司 and Sangel Capital

S

Sirnaomics, Inc. raised $105M on October 23, 2020

Investors: 阳光融汇资本投资管理有限公司 and Sangel Capital

V

Virogin Biotech Ltd raised undisclosed on June 7, 2020

Investors: Sangel Capital

D

Denovo Biopharma raised $43M on October 31, 2019

Investors: 广州越秀产业投资基金管理有限公司 and Sangel Capital

U

Undisclosed raised $15M on February 13, 2019

Investors: Sangel Capital

慧渡(上海)医疗科技有限公司 raised undisclosed on August 6, 2018

Investors: Sangel Capital

FAQ